AstraZeneca's Breztri aces 2 asthma trials, lining it up for label expansion
AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion, revealing the success of two trials investigating Breztri as a treatment for asthma.
AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion, revealing the success of two trials investigating Breztri as a treatment for asthma.
